Marinus Pharmaceuticals Return on Equity

Marinus Pharmaceuticals (MRNS) currently reports a ROE of 210.5%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Marinus Pharmaceuticals's ROE history and peer comparisons.

Marinus Pharmaceuticals's ROE of 210.5% is higher than the Healthcare sector average of 11.15%. That is roughly 1787.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Marinus Pharmaceuticals's current 210.5% should be judged against Healthcare norms (sector average: 11.15%) and against MRNS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 210.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Marinus Pharmaceuticals, and consider following MRNS for alerts when major investors trade the stock.

Marinus Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 210.5% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRNS with unrelated industries.